

Publications to which infrastructure grants have contribute to up to March 2025

1. Amary MF, Perez-Casanova L, Ye H, Cottone L, Strobl A, Cool P, Miranda E, Berisha F, Aston W, Rocha M, O'Donnell P, Pillay N, Tirabosco R, Baumhoer D, Hookway E, Flanagan AM. Synovial chondromatosis and soft tissue chondroma: extra-osseous cartilaginous tumours defined by *FN1* gene rearrangement. *Modern Pathology* **2019**; 32(7):1-10. doi: 10.1038/s41379-019-0315-8.
2. Steele CD, Tarabichi M, Oukrif D, Webster AP, Ye H, Fittall M, Lombard P, Martincorena I, Tarpey PS, Collord G, Haase K, Strauss S, Berisha F, Vaikkinen H, Dhami P, Jansen M, Behjati S, Amary MF, Tirabosco R, Feber A, Campbell PJ, Alexandrov LB, Van Loo P, Flanagan AM, Pillay N. Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. *Cancer Cell*, **2019**; 18;35(3):441-456.e8. doi: [10.1016/j.ccell.2019.02.00](https://doi.org/10.1016/j.ccell.2019.02.00).
3. Ali NM, Niada S, Morris MR, Brini AT, Huen D, Sumathi V, Latif F. Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors. *Am J Surg Pathol.*, **2019**; Jul;43(7):965-974. doi: 10.1097/PAS.0000000000001251.
4. Cottone L, Cribbs AP, Khandelwal G, Wells G, Ligammari L, Philpott M, Tumber A, Lombard P, Hookway ES, Szommer T, Johansson C, Brennan PE, Pillay N, Jenner RG, Oppermann U, Flanagan AM. Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death. *Cancer Research*, **2020**; Oct 15;80(20):4540-455. <https://doi.org/10.1158/0008-5472.CAN-20-1387>.
5. Mirabello L , Zhu B, Koster R, Karlins E, Dean M, Yeager M, Gianferante M, Spector LG, Morton LM, Karyadi , D, Robison LR, Armstrong G T, Bhatia S, Song L , Pankratz N, Pinheiro M , Gastier-Foster J M, Gorlick R, Caminada de Toledo SR, Petrilli AS , Patino-Garcia A, Lecanda, Gutierrez-Jimeno M, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF , Kurucu N, Ilhan E, Ballinger ML, Thomas DM, Barkauskas DA, Mejia-Baltodano G, Valverde , Hicks BD, Wang M, Hutchinson AA , Tucker M, Sampson J , Landi MT, Freedman ND, Gapstur S, Carter B, Hoover RN, Chanock SJ, Savage SA- Frequency of Pathogenic Germline Variants in Cancer Susceptibility Genes in Patients with Osteosarcoma, *JAMA Oncology* **2020**; 6(5):724-734. doi:10.1001/jamaoncol.2020.0197.
6. Fittall MW, Lyskjaer I, Ellery P, Lombard P, Ijaz J, Strobl AC, Oukrif D, Tarabichi M, Sill M, Koelsche C, Mechttersheimer G, Demeulemeester J, Tirabosco R, Amary F, Campbell PJ, Pfister SM, Jones DT, Pillay N, Van Loo P, Behjati S, Flanagan AM. Drivers underpinning the malignant transformation of giant cell tumour of bone. *J Pathol.*, **2020**; Dec;252(4):433-440. doi: 10.1002/path.5537.
7. Prendergast SC, Strobl AC, Cross W , Pillay N, Strauss SJ, Ye H, Lindsay D, Tirabosco R, Chalker J, Mahamdallie SS, Sosinsky A, RNOH Pathology Laboratory and Biobank Team, Genomics England Research Consortium, Adrienne M Flanagan AM, Amary F. Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. *The Journal of Pathology: Clinical Research*, **2020**; (6), 297-307. <https://doi.org/10.1002/cjp2.174> .

8. Green D, Eyre H, Singh A, Taylor JT, Chu J, Jeys L, Sumathi V, Coonar A, Rassl D, Babur M, Forster D, Alzabin S, Ponthan F, McMahon A, Bigger B, Reekie T, Kassiou M, Williams K, Dalmay T, Fraser WD, Finegan KG. Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. *Oncogene*, **2020**; **39**, 5553–5569. <https://doi.org/10.1038/s41388-020-1379-0>.
9. De Noon S, Ijaz J, Coorens THH, Amary F, Ye H, Strobl A, Lyskjær I, Flanagan AM, Behjati S. MYC amplifications are common events in childhood osteosarcoma. *The Journal of Pathology: Clinical Research*, **2021**; (7), 425–431. <https://doi.org/10.1002/cjp2.219>.
10. Lyskjær I, Solange De Noon S, Tirabosco R, Rocha AM, Lindsay D, Amary F, Ye H, Schrimpf D, Stichel D, Sill M, Koelsche C, Pillay N, Deimling AV, Beck S, Flanagan AM. DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the 'DKFZ Sarcoma Classifier'. *The Journal of Pathology: Clinical Research*, **2021**; (7), 350–360. <https://doi.org/10.1002/cjp2.215>.
11. De Noon S, Flanagan AM, Tirabosco R, O'Donnell P, Amary F. EWSR1-SMAD3 fibroblastic tumour of bone: expanding the clinical spectrum. *Skeletal Radiology*, **2021**; 50, 445–450. <https://doi.org/10.1007/s00256-020-03563-0>.
12. Lyskjær I, Davies C, Strobl AC, Hindley J, James S, Lalam RK, Cross W, Hide G, Rankin KS, Jeys L, Tirabosco R, Stevenson J; Genomics England Research Consortium; O'Donnell P, Cool P, Flanagan AM. Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations. *Mol Oncol.*, **2021**; Dec;15(12):3679-3690. doi: 10.1002/1878-0261.13102.
13. Cottone L, Ligammari L, Lee HM, Knowles HJ, Henderson S, Bianco S, Davies C, Strauss S, Amary F, Leite AP, Tirabosco R, Haendler K, Schultze JL, Herrero J, O'Donnell P, Grigoriadis AE, Salomoni P, Flanagan AM. Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone. *Cell Death & Differentiation*, **2022**; 29, 2459–2471. <https://doi.org/10.1038/s41418-022-01031-x>.
14. Lyskjær I, Kara N, De Noon S, Davies C, Rocha AM, Strobl AC, Usher I, Gerrand C, Strauss SJ, Schrimpf D, Deimling AV, Beck S, Flanagan AM. Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. *European Journal of Cancer*, **2022**; (168), 1–11. <https://doi.org/10.1016/j.ejca.2022.03.002>
15. Beird HC, S. Bielack S, Flanagan AM, Gill J, Heymann D, Janeway KA, J. Livingston A, Roberts RD, Sandra J. Strauss SJ, Gorlick R. Osteosarcoma. *Nat. Rev. Dis. Primers*, **2022**; 8, 82. <https://doi.org/10.1038/s41572-022-00416-z>.
16. Usher I, Ligammari L, Ahrabi S, Hepburn E, Connolly C, Bond GL, Flanagan AM, Cottone L. Optimizing CRISPR/Cas9 Editing of Repetitive Single Nucleotide Variants. *Front Genome Ed.*, **2022**; Jul 5;4:932434. doi: 10.3389/fgeed.2022.932434.
17. Cross W, Ien Lyskjær I, Lesluyes T, Hargreaves S, Strobl AC, Davies C, Waise S, Hames-Fathi S, Oukrif D, Ye H, Amary F, Tirabosco R, Gerrand C, Baker T, David Barnes D, Steele C, Alexandrov L, Bond G, Genomics England Research Consortium, Cool P, Pillay N, Van Loo P, Flanagan AM. A genetic model for central chondrosarcoma evolution correlates with patient outcome. *Genome Med.*, **2022**; 14, 99. <https://doi.org/10.1186/s13073-022-01084-0>.
18. De Noon S, Piggott R, Trotman J, Tadross JA, Fittall M, Hughes D, Ye H, Munasinghe E, Murray M, Tirabosco R, Amary F, Coleman N, Watkins J, Hubank M, Tarpey P,

Behjati S, Flanagan AM. Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma. *J Pathol.*, **2023**; Feb;259(2):119-124. doi: 10.1002/path.6038.

19. Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM, Chatzipli A, Dickson BC, Borcharding DC, Feber A, Galor A, Hart J, Jones KB, Jordan JT, Kim RH, Lindsay D, Miller C, Nishida Y, Proszek PZ, Serrano J, Sundby RT, Szymanski JJ, Ullrich NJ, Viskochil D, Wang X, Snuderl M, Park PJ, Flanagan AM, Hirbe AC, Pillay N, Miller DT; Genomics of MPNST (GeM) Consortium. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. *Cancer Discov.*, **2023**; Mar 1;13(3):654-671. doi: 10.1158/2159-8290.CD-22-0786.
20. Souza L, Ferreira. FV, Lopes JH, Camilli JA, Martin RA. Cancer Inhibition and In Vivo Osteointegration and Compatability of Gallium-Doped Bioactive Glasses for Osteosarcoma Applications. *ACS applied materials & Interfaces*, **2022**; Vol 14/ issue 40 2022.
21. Raja FN, Worthington T, Souza L, Hanaei SB, Martin R. Synergistic Antimicrobial Metal Oxide-Doped Phosphate Glasses; a Potential Strategy to Reduce Antimicrobial Resistance and Host Cell Toxicity. *ACS Biomaterials Science & Engineering*. *ACS Biomaterials Science & Engineering*, **2022**; vol 8/issue 3. DOI:10.1021/acsbomaterials.1c00876.
22. Souza L, Ferreira FV, Lopes JH, Camilli JA, and Martin R. Cancer Inhibition and In Vivo Osteointegration and Compatibility of Gallium-Doped Bioactive Glasses for Osteosarcoma Applications *Applied Materials and Interfaces*, **2022**; Vol 14/Issue 40. DOI:10.1021/acssami.2c12102.
23. Brookes MJ, Roundhill EA, Jeys L, Parry M, Burchill SA, Rankin KS. Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma. *Pediatr. Blood Cancer*. **2022**; Dec;69(12): e29959. doi: 10.1002/pbc.29959.
24. Authors: Guilherme S. Medeiros, Luis F. Oliveira, Filipe V. Ferreira, Souza LP, Martin RA, Oliveira IE, Lopes JH. A perfect pair: Niobium- and gallium-doped ceramic biomaterial enabled by coupled synthesis method with potential application for bone regeneration and cancer-targeted therapy. *Journal of Non- Crystalline Solids*, **2023**; Volume 599, 1, 121962. DOI:10.1016/j.jnoncrysol.2022.121962.
25. Green D, Singh A, Tippet VL, Tattersall L, Shah KM, Siachisumo C, Ward NJ, Thomas P, Carter S, Jeys L, Sumathi V, McNamara I, Elliott DJ, Gartland A, Dalmay T, Fraser WD. YBX1-interacting small RNAs and *RUNX2* can be blocked in primary bone cancer using CADD522. *J Bone Oncol.*, **2023**; Mar 5;39:100474. doi: 10.1016/j.jbo.2023.100474.
26. Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM, Chatzipli A, Dickson BC, Borcharding DC, Feber A, Galor A, Hart J, Jones KB, Jordan JT, Kim RH, Lindsay D, Miller C, Nishida Y, Proszek PZ, Serrano J, Sundby RT, Szymanski JJ, Ullrich NJ, Viskochil D, Wang X, Snuderl M, Park PJ, Flanagan AM, Hirbe AC, Pillay N, Miller DT; Genomics of MPNST (GeM) Consortium. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. *Cancer Discov.*, **2023**; Mar 1;13(3):654-671. doi: 10.1158/2159-8290.CD-22-0786.
27. Beird HC, Wu CC, Nakazawa M, Ingram D, Daniele JR, Lazcano R, Little L, Davies C, Daw NC, Wani K, Wang WL, Song X, Gumbs C, Zhang J, Rubin B, Conley A, Flanagan AM, Lazar AJ, Futreal PA. Complete loss of *TP53* and *RB1* is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. *HGG Adv.*, **2023**; Jul 19;4(4):100224. doi: 10.1016/j.xhgg.2023.100224.

28. De Noon S, Piggott R, Trotman J, Tadross JA, Fittall M, Hughes D, Ye H, Munasinghe E, Murray M, Tirabosco R, Amary F, Coleman N, Watkins J, Hubank M, Tarpey P, Behjati S, Flanagan AM. Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma. *J Pathol.*, **2023**; Feb;259(2):119-124. doi: 10.1002/path.6038.
25. Ferreira FV, Souza AG, Ajdary R, de Souza LP, Lopes JH, Correa DS, Siqueira G, Barud HS, Rosa DDS, Mattoso LHC, Rojas OJ. Nanocellulose-based porous materials: Regulation and pathway to commercialization in regenerative medicine. *Bioact Mater.*, **2023**; Jul 12;29:151-176. doi: 10.1016/j.bioactmat.2023.06.020.
26. Homer WJA, Lisnenko M, Gardner AC, Kostakova EK, Valtera J, Wall IB, Jencova V, Topham PD, Theodosiou E. Assessment of thermally stabilized electrospun poly(vinyl alcohol) materials as cell permeable membranes for a novel blood salvage device. *Biomater Adv.*, **2023**; Jan;144:213197. doi: 10.1016/j.bioadv.2022.213197.
27. Pal R, Lwin TM, Krishnamoorthy M, Collins HR, Chan CD, Prilutskiy A, Nasrallah MP, Dijkhuis TH, Shukla S, Kendall AL, Marshall MS, Carp SA, Hung YP, Shih AR, Martinez-Lage M, Zukerberg L, Sadow PM, Faquin WC, Nahed BV, Feng AL, Emerick KS, Mieog JSD, Vahrmeijer AL, Rajasekaran K, Lee JYK, Rankin KS, Lozano-Calderon S, Varvares MA, Tanabe KK, Kumar ATN. Fluorescence lifetime of injected indocyanine green as a universal marker of solid tumours in patients. *Nat Biomed Eng.*, **2023**; Dec;7(12):1649-1666. doi: 10.1038/s41551-023-01105-2.
28. Salomoni P, Flanagan AM, Cottone L. (B)On(e)-cohistones and the epigenetic alterations at the root of bone cancer. *Cell Death Differ.*, **2023**; Jan;32(1):66-77. doi: 10.1038/s41418-023-01227-9.
29. Homer WJA, Lisnenko M, Hauzerova S, Heczko B, Gardner AC, Kostakova EK, Topham PD, Jencova V, Theodosiou E. Thermally Stabilised Poly(vinyl alcohol) Nanofibrous Materials Produced by Scalable Electrospinning: Applications in Tissue Engineering. *Polymers (Basel)*, **2024**; Jul 21;16(14):2079. doi: 10.3390/polym16142079.
30. Hanaei SB, Murugesan RC, Souza LP, Cadiz-Miranda JI, Jeys L, Wall IB, Martin RA. Multifunctional gallium doped bioactive glasses: a targeted delivery for antineoplastic agents and tissue repair against osteosarcoma. *Biomed Mater.*, **2024**; Sep 17;19(6). doi: 10.1088/1748-605X/ad76f1.
31. Shen Z, Simard M, Brand D, Andrei V, Al-Khader A, Oumlil F, Trevers K, Butters T, Haefliger S, Kara E, Amary F, Tirabosco R, Cool P, Royle G, Hawkins MA, Flanagan AM, Collins-Fekete CA. A deep learning framework deploying segment anything to detect pan-cancer mitotic figures from haematoxylin and eosin-stained slides. *Commun Biol.*, **2024**; 19;7(1):1674. doi: 10.1038/s42003-024-07398-6.
32. Espejo Valle-Inclan J, De Noon S, Trevers K, Elrick H, van Belzen IAEM, Zumalave S, Sauer CM, Tanguy M, Butters T, Muyas F, Rust AG, Amary F, Tirabosco R, Giess A, Sosinsky A, Elgar G, Flanagan AM, Cortés-Ciriano I. Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution. *Cell*, **2025**; Jan 23;188(2):352-370.e22. doi: 10.1016/j.cell.2024.12.005.